Treats acute decompensated heart failure. ANDA 75936, held by Fresenius Kabi USA. Milrinone Lactate.
As of Nov 16, 2026, ANDA 75936 (Milrinone Lactate), held by Fresenius Kabi USA, was first approved by FDA on May 28, 2002, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE: Milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 28, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Milrinone LactateEQ 1MG BASE/ML · injectable;injection | Milrinone Lactate | Rx |
| Feb 8, 2007 | Supplement 2Labeling | Approved | None posted |
| May 28, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters